Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CPRX

Catalyst Pharmaceuticals Inc

Mar 19 • 04:00PM ET

22.60

Dollar change +0.52
Percentage change 2.36	%

Healthcare • Biotechnology • USA • NASD

Peers: AXSM AMLX SUPN ENTA ITCI PRTA RDUS XENE ALKS

| Held by: IJR VTI IWM CALF VXF XBI IJT SPSM IWO SLYG

Scroll to Statements

Index	RUT	P/E	17.27	EPS (ttm)	1.31	Insider Own	8.89%	Shs Outstand	120.88M	Perf Week	6.60%
Market Cap	2.74B	Forward P/E	13.73	EPS next Y	1.65	Insider Trans	-10.37%	Shs Float	110.65M	Perf Month	-1.44%
Income	163.89M	PEG	1.66	EPS next Q	0.34	Inst Own	78.80%	Short Float	5.63%	Perf Quarter	5.71%
Sales	491.73M	P/S	5.58	EPS this Y	7.85%	Inst Trans	2.50%	Short Ratio	5.23	Perf Half Y	10.57%
Book/sh	6.02	P/B	3.75	EPS next Y	16.48%	ROA	24.71%	Short Interest	6.23M	Perf Year	40.63%
Cash/sh	4.26	P/C	5.30	EPS next 5Y	10.39%	ROE	29.38%	52W Range	14.47 - 24.64	Perf YTD	8.29%
Dividend Est.	-	P/FCF	11.47	EPS past 5Y	34.27%	ROI	22.44%	52W High	-8.28%	Beta	0.84
Dividend TTM	-	Quick Ratio	5.01	Sales past 5Y	39.23%	Gross Margin	78.40%	52W Low	56.19%	ATR (14)	0.82
Dividend Ex-Date	-	Current Ratio	5.17	EPS Y/Y TTM	104.96%	Oper. Margin	39.68%	RSI (14)	56.44	Volatility	3.02% 3.73%
Employees	181	Debt/Eq	0.00	Sales Y/Y TTM	23.49%	Profit Margin	33.33%	Recom	1.12	Target Price	33.62
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	44.63%	Payout	0.00%	Rel Volume	0.84	Prev Close	22.08
Sales Surprise	5.69%	EPS Surprise	29.95%	Sales Q/Q	28.26%	Earnings	Feb 26 AMC	Avg Volume	1.19M	Price	22.60
SMA20	4.63%	SMA50	1.75%	SMA200	12.31%	Trades		Volume	1,003,111	Change	2.36%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-04-25	Initiated	Robert W. Baird	Outperform	$28
Nov-18-24	Initiated	Stephens	Overweight	$35
Mar-14-24	Initiated	Citigroup	Buy	$27
Mar-07-24	Initiated	BofA Securities	Buy	$23
Dec-21-23	Initiated	Oppenheimer	Outperform	$30
Aug-24-22	Downgrade	ROTH Capital	Buy → Neutral	$10 → $15.50
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Sep-07-18	Resumed	Piper Jaffray	Overweight
Oct-05-16	Upgrade	Piper Jaffray	Neutral → Overweight
Apr-26-16	Downgrade	Piper Jaffray	Overweight → Neutral	$6 → $1
Sep-30-14	Reiterated	ROTH Capital	Buy	$5 → $6
Sep-16-14	Reiterated	ROTH Capital	Buy	$3.50 → $5
Sep-15-14	Reiterated	H.C. Wainwright	Buy	$5 → $13
Oct-21-13	Reiterated	Aegis Capital	Buy	$4 → $5.50
Sep-24-13	Initiated	Maxim Group	Buy	$4
Sep-06-13	Reiterated	Aegis Capital	Buy	$3.50 → $4
Apr-18-13	Initiated	Aegis Capital	Buy	$2.50
Aug-27-12	Upgrade	Rodman & Renshaw	Mkt Perform → Mkt Outperform	$3.70
Oct-01-09	Upgrade	Merriman	Sell → Neutral
May-29-09	Downgrade	Merriman Curhan Ford	Buy → Sell

Show Previous Ratings

Mar-14-25 10:54AM	Is Catalyst Pharmaceuticals, Inc. (CPRX) the Best Healthcare Stock For Long-Term Investment? (Insider Monkey)
Mar-04-25 08:03AM	Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference (GlobeNewswire)
Feb-28-25 02:14AM	Catalyst Pharmaceuticals Inc (CPRX) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) +5.68%
Feb-27-25 02:35PM	Here's What's Driving Catalyst Pharmaceuticals Stock 8% Higher Today (Motley Fool) +5.25%
Feb-26-25 08:30PM	Catalyst (CPRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
06:50PM	Loading…
06:50PM	Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates (Zacks)
05:53PM	Catalyst: Q4 Earnings Snapshot (Associated Press Finance)
04:13PM	Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
07:31AM	Catalyst Pharmaceuticals Inc (CPRX) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-25-25 10:23AM	Catalyst Pharmaceuticals Inc (CPRX) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-18-25 04:25PM	Recursion Pharmaceuticals Stock Scores RS Ratings Over 90 (Investor's Business Daily)
04:16PM	Incyte Stock Sees Relative Strength Rating Rise To 71 (Investor's Business Daily)
Feb-12-25 08:03AM	Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025 (GlobeNewswire)
Jan-31-25 08:00AM	This Drug Stock Sits On A Strong Earnings Foundation As It Tests New Entry (Investor's Business Daily)
Jan-30-25 03:32PM	Harmony Biosciences Stock Scores 80-Plus RS Rating (Investor's Business Daily)
09:50AM	Loading…
Jan-24-25 09:50AM	Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock (Zacks)
Jan-23-25 08:03AM	Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies (GlobeNewswire)
Jan-21-25 08:19AM	Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE in Japan (GlobeNewswire)
Jan-15-25 03:44PM	BeiGene Stock Meets 80-Plus RS Rating Benchmark (Investor's Business Daily)
Jan-14-25 03:30PM	BridgeBio Pharma Stock Earns 87 RS Rating (Investor's Business Daily)
Jan-09-25 08:17AM	Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock? (Zacks)
Jan-08-25 04:10PM	IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva (Investor's Business Daily) +16.74%
12:30PM	Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE (amifampridine) Patent Litigation with Teva Pharmaceuticals (GlobeNewswire)
Jan-07-25 09:45AM	Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock (Zacks)
Dec-27-24 02:09PM	Arcellx Stock Earns 82 Relative Strength Rating (Investor's Business Daily)
Dec-24-24 03:23PM	Neurocrine Biosciences Stock Sees RS Rating Upgrade (Investor's Business Daily)
09:50AM	Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term (Zacks)
Dec-18-24 09:40AM	Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock (Zacks)
Dec-16-24 08:03AM	Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-24 03:06PM	NewAmsterdam Pharma Stock Hits 90-Plus RS Rating (Investor's Business Daily)
11:31AM	Loading…
Dec-06-24 11:31AM	Why Is Catalyst (CPRX) Down 6.7% Since Last Earnings Report? (Zacks)
Dec-02-24 02:21PM	Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term (Zacks)
Nov-27-24 09:50AM	Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock (Zacks)
Nov-25-24 08:03AM	Catalyst Pharmaceuticals Recognized as One of North America's Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500 List (GlobeNewswire)
Nov-19-24 08:03AM	Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-15-24 09:45AM	Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock (Zacks) -5.03%
Nov-13-24 08:03AM	Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work (GlobeNewswire)
Nov-11-24 02:06PM	Vericel Stock Sees RS Rating Shoot Higher (Investor's Business Daily)
Nov-10-24 06:00PM	Catalyst Pharmaceuticals Inc (CPRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-07-24 09:15AM	Catalyst Pharmaceuticals, Inc. (CPRX) Hit a 52 Week High, Can the Run Continue? (Zacks)
Nov-06-24 06:00PM	Catalyst (CPRX) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
05:25PM	Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings and Revenue Estimates (Zacks)
04:22PM	Catalyst: Q3 Earnings Snapshot (Associated Press Finance)
04:12PM	Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
07:13AM	Catalyst Pharmaceuticals Inc (CPRX) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Oct-22-24 08:03AM	Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024 (GlobeNewswire)
Oct-08-24 08:03AM	Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts (GlobeNewswire)
Oct-01-24 12:00PM	Catalyst (CPRX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
08:03AM	Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024 (GlobeNewswire)
Sep-24-24 06:00AM	Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE in Japan (GlobeNewswire)
Sep-12-24 01:00AM	Santhera Announces Half-Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Sep-06-24 11:31AM	Why Is Catalyst (CPRX) Up 8.3% Since Last Earnings Report? (Zacks)
Aug-22-24 07:01PM	Insider Sale at Catalyst Pharmaceuticals Inc (CPRX): Chief Operating & Scientific Officer ... (GuruFocus.com)
Aug-20-24 08:03AM	Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-15-24 09:55AM	Wall Street Analysts See a 56.65% Upside in Catalyst (CPRX): Can the Stock Really Move This High? (Zacks)
Aug-07-24 08:30PM	Catalyst (CPRX) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks) +12.75%
07:40PM	Catalyst Pharmaceutical (CPRX) Beats Q2 Earnings and Revenue Estimates (Zacks)
06:36PM	Catalyst: Q2 Earnings Snapshot (Associated Press Finance)
04:11PM	Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-24-24 08:05AM	Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE in Canada (GlobeNewswire)
Jul-22-24 08:03AM	Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024 (GlobeNewswire)
Jun-07-24 11:30AM	Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report? (Zacks)
May-30-24 01:41PM	Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE (GlobeNewswire)
May-28-24 08:03AM	Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024 (GlobeNewswire)
May-15-24 08:00AM	2 Incredible Growth Stocks to Buy Hand Over Fist Right Now (Motley Fool)
May-10-24 05:20PM	Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 11:40AM	Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues (Zacks) +6.32%
May-08-24 05:04PM	Catalyst: Q1 Earnings Snapshot (Associated Press Finance)
04:16PM	Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-01-24 10:01AM	Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
08:00AM	Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024 (GlobeNewswire)
Apr-25-24 01:00AM	Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May (GlobeNewswire)
Apr-24-24 01:45PM	Dirt-Cheap Delights: 3 Discounted Stocks That Could Triple by 2026 (InvestorPlace)
Apr-22-24 08:00AM	Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024 (GlobeNewswire)
Apr-13-24 12:18PM	Jim Cramer's 10 Favorite Healthcare Stock Picks in 2024 (Insider Monkey)
Mar-29-24 11:30AM	Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report? (Zacks)
Mar-28-24 08:03AM	Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day (GlobeNewswire)
Mar-27-24 08:03AM	Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium (GlobeNewswire)
07:44AM	3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List (InvestorPlace)
Mar-18-24 08:01PM	7 Biotech Stocks Ready to Ride the Sectors Resurgence (InvestorPlace)
Mar-14-24 02:00AM	Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE (Vamorolone) in the United States (GlobeNewswire)
Mar-13-24 07:55AM	Catalyst Pharmaceuticals Announces AGAMREE Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD) (GlobeNewswire)
Mar-10-24 03:24PM	3 Sexy Small-Cap Stocks to Add Sizzle to Your Portfolio (InvestorPlace)
Mar-05-24 08:03AM	Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference (GlobeNewswire)
Feb-29-24 12:10PM	Catalyst (CPRX) Q4 Earnings & Sales Beat Estimates, Stock Up (Zacks) +10.10%
Feb-28-24 07:20PM	Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates (Zacks)
06:35PM	Catalyst: Q4 Earnings Snapshot (Associated Press Finance)
06:03PM	Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-27-24 08:03AM	Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE (GlobeNewswire)
Feb-21-24 09:00AM	Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical's VISION-DMD Vamorolone (AGAMREE ) Study Results in the Peer-Reviewed Journal Neurology (GlobeNewswire)
Feb-14-24 08:03AM	Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024 (GlobeNewswire)
Jan-18-24 09:50AM	Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term (Zacks)
04:54AM	Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances (InvestorPlace)
Jan-15-24 08:45AM	3 Biotech Stocks You Can Buy and Hold for the Next Decade (Motley Fool)
Jan-14-24 08:40AM	Forget Shiba Inu: This Stock is Poised for a Potential Bull Run in 2024 (Motley Fool)
Jan-12-24 09:45AM	Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term (Zacks)
Jan-09-24 04:57PM	Catalyst (CPRX) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
04:05PM	Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering (GlobeNewswire)
Jan-08-24 08:55AM	3 Unstoppable S&P 600 Small-Cap Stocks to Buy in January (InvestorPlace)
Jan-05-24 08:02AM	Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -14.85%

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
INGENITO GARY	Chief Med. & Reg. Officer	Mar 06 '25	Option Exercise	2.24	180,096	403,415	248,969	Mar 07 05:00 PM
INGENITO GARY	Chief Med. & Reg. Officer	Mar 05 '25	Option Exercise	2.24	44,904	100,585	113,777	Mar 07 05:00 PM
INGENITO GARY	Chief Med. & Reg. Officer	Mar 06 '25	Sale	21.67	180,096	3,902,680	68,873	Mar 07 05:00 PM
INGENITO GARY	Chief Med. & Reg. Officer	Mar 05 '25	Sale	22.09	44,904	991,929	68,873	Mar 07 05:00 PM
INGENITO GARY	Officer	Mar 06 '25	Proposed Sale	21.67	180,096	3,903,251		Mar 06 04:17 PM
Elsbernd Brian	Chief Compliance/Legal Officer	Mar 03 '25	Option Exercise	2.24	62,525	140,056	241,819	Mar 05 05:00 PM
Elsbernd Brian	Chief Compliance/Legal Officer	Mar 03 '25	Sale	22.98	62,975	1,446,933	188,564	Mar 05 05:00 PM
Del Carmen Jeffrey	Chief Commercial Officer	Mar 03 '25	Sale	22.89	30,423	696,382	0	Mar 05 05:00 PM
INGENITO GARY	Officer	Mar 05 '25	Proposed Sale	22.09	44,904	991,911		Mar 05 04:09 PM
Elsbernd Brian	Officer	Mar 03 '25	Proposed Sale	22.97	62,525	1,436,446		Mar 03 04:21 PM
Del Carmen Jeffrey	Officer	Mar 03 '25	Proposed Sale	22.89	30,423	696,382		Mar 03 10:21 AM
DENKHAUS DONALD A	Director	Jan 08 '25	Option Exercise	2.24	50,000	112,000	491,079	Jan 10 05:00 PM
Miller Steve	Chief Op. & Scientific Officer	Dec 13 '24	Option Exercise	4.01	235,000	942,350	921,996	Dec 17 05:24 PM
Miller Steve	Chief Op. & Scientific Officer	Dec 10 '24	Option Exercise	4.01	50,000	200,500	736,996	Dec 11 05:00 PM
Miller Steve	Chief Op. & Scientific Officer	Dec 10 '24	Sale	21.93	50,000	1,096,350	686,996	Dec 11 05:00 PM
O'Keeffe Charles B	Director	Dec 10 '24	Option Exercise	4.01	40,000	160,400	727,137	Dec 11 05:00 PM
Miller Steve	Officer	Dec 10 '24	Proposed Sale	21.93	50,000	1,096,333		Dec 10 12:55 PM
INGENITO GARY	Chief Med. & Reg. Officer	Nov 27 '24	Option Exercise	4.01	12,000	48,120	63,391	Nov 29 08:09 PM
INGENITO GARY	Chief Med. & Reg. Officer	Nov 27 '24	Sale	22.72	12,000	272,654	51,391	Nov 29 08:09 PM
Harper Molly	Director	Nov 27 '24	Option Exercise	5.78	17,500	101,150	17,500	Nov 29 08:09 PM
Harper Molly	Director	Nov 27 '24	Sale	22.00	17,500	385,000	0	Nov 29 08:09 PM
Elsbernd Brian	Chief Compliance/Legal Officer	Nov 26 '24	Option Exercise	4.01	60,000	240,600	175,133	Nov 29 08:08 PM
Elsbernd Brian	Chief Compliance/Legal Officer	Nov 26 '24	Sale	21.63	13,256	286,704	165,377	Nov 29 08:08 PM
INGENITO GARY	Officer	Nov 27 '24	Proposed Sale	22.72	12,000	272,653		Nov 27 02:42 PM
Harper Molly	Director	Nov 27 '24	Proposed Sale	22.00	17,500	385,000		Nov 27 09:42 AM
Elsbernd Brian	Officer	Nov 26 '24	Proposed Sale	21.63	13,256	286,705		Nov 26 12:37 PM
INGENITO GARY	Chief Med. & Reg. Officer	Nov 20 '24	Option Exercise	4.01	38,000	152,380	89,391	Nov 22 05:00 PM
INGENITO GARY	Chief Med. & Reg. Officer	Nov 20 '24	Sale	21.20	38,000	805,562	51,391	Nov 22 05:00 PM
MCENANY PATRICK J	Chairman of Board of Directors	Nov 19 '24	Option Exercise	3.54	98,345	348,141	4,576,514	Nov 21 05:11 PM
MCENANY PATRICK J	Chairman of Board of Directors	Nov 20 '24	Option Exercise	3.54	72,500	256,650	4,550,669	Nov 21 05:11 PM
MCENANY PATRICK J	Chairman of Board of Directors	Nov 19 '24	Sale	21.19	98,345	2,083,734	4,478,169	Nov 21 05:11 PM
MCENANY PATRICK J	Chairman of Board of Directors	Nov 20 '24	Sale	21.29	72,500	1,543,525	4,478,169	Nov 21 05:11 PM
INGENITO GARY	Officer	Nov 20 '24	Proposed Sale	21.20	38,000	805,543		Nov 20 03:49 PM
MCENANY PATRICK J	Director	Nov 20 '24	Proposed Sale	21.29	72,500	1,543,555		Nov 20 02:57 PM
MCENANY PATRICK J	Director	Nov 19 '24	Proposed Sale	21.19	98,345	2,083,726		Nov 19 04:09 PM
MCENANY PATRICK J	Chairman of Board of Directors	Nov 13 '24	Option Exercise	3.54	92,500	327,450	4,570,669	Nov 15 05:00 PM
MCENANY PATRICK J	Chairman of Board of Directors	Nov 14 '24	Option Exercise	3.54	44,655	158,079	4,522,824	Nov 15 05:00 PM
MCENANY PATRICK J	Chairman of Board of Directors	Nov 13 '24	Sale	22.98	92,500	2,125,465	4,478,169	Nov 15 05:00 PM
MCENANY PATRICK J	Chairman of Board of Directors	Nov 14 '24	Sale	21.75	44,655	971,336	4,478,169	Nov 15 05:00 PM
MCENANY PATRICK J	Director	Nov 14 '24	Proposed Sale	21.75	44,655	971,327		Nov 14 04:12 PM
MCENANY PATRICK J	Chairman of Board of Directors	Nov 12 '24	Option Exercise	3.67	262,000	960,380	4,670,169	Nov 13 05:44 PM
MCENANY PATRICK J	Chairman of Board of Directors	Nov 11 '24	Option Exercise	4.01	230,000	922,300	4,708,169	Nov 13 05:44 PM
MCENANY PATRICK J	Chairman of Board of Directors	Nov 12 '24	Sale	23.26	262,000	6,094,062	4,478,169	Nov 13 05:44 PM
MCENANY PATRICK J	Chairman of Board of Directors	Nov 11 '24	Sale	23.55	230,000	5,416,040	4,478,169	Nov 13 05:44 PM
MCENANY PATRICK J	Former Director	Nov 13 '24	Proposed Sale	22.98	92,500	2,125,997		Nov 13 04:04 PM
MCENANY PATRICK J	Director	Nov 12 '24	Proposed Sale	23.16	70,000	1,620,856		Nov 12 04:11 PM
MCENANY PATRICK J	Director	Nov 12 '24	Proposed Sale	23.30	192,000	4,473,224		Nov 12 02:13 PM
MCENANY PATRICK J	Director	Nov 11 '24	Proposed Sale	23.55	230,000	5,416,009		Nov 12 10:52 AM
Tierney David S	Director	Aug 21 '24	Option Exercise	4.01	15,000	60,150	363,874	Aug 23 05:00 PM
Tierney David S	Director	Aug 21 '24	Sale	20.10	15,000	301,455	348,874	Aug 23 05:00 PM
Miller Steve	Chief Op. & Scientific Officer	Aug 20 '24	Sale	20.35	150,000	3,052,900	675,124	Aug 22 05:00 PM
Tierney David S	Director	Aug 21 '24	Proposed Sale	20.10	15,000	301,450		Aug 21 02:21 PM
Miller Steve	Officer	Aug 20 '24	Proposed Sale	20.37	150,000	3,055,849		Aug 20 04:42 PM
Del Carmen Jeffrey	Chief Commercial Officer	Aug 09 '24	Option Exercise	2.86	30,000	85,800	42,369	Aug 13 05:01 PM
Del Carmen Jeffrey	Chief Commercial Officer	Aug 09 '24	Sale	18.42	36,058	664,310	12,369	Aug 13 05:01 PM
INGENITO GARY	Chief Med. & Reg. Officer	Aug 09 '24	Option Exercise	4.01	100,000	401,000	151,391	Aug 13 05:01 PM
INGENITO GARY	Chief Med. & Reg. Officer	Aug 09 '24	Sale	18.04	100,000	1,804,000	51,391	Aug 13 05:01 PM
INGENITO GARY	Officer	Aug 09 '24	Proposed Sale	18.03	100,000	1,803,262		Aug 09 02:53 PM
Del Carmen Jeffrey	Officer	Aug 09 '24	Proposed Sale	18.42	36,058	664,348		Aug 09 11:24 AM
Del Carmen Jeffrey	Chief Commercial Officer	Jun 07 '24	Sale	16.07	7,541	121,184	18,427	Jun 11 05:00 PM
INGENITO GARY	Chief Med. & Reg. Officer	Jun 05 '24	Option Exercise	4.01	80,000	320,800	131,391	Jun 07 05:00 PM
INGENITO GARY	Chief Med. & Reg. Officer	Jun 05 '24	Sale	16.16	80,000	1,292,800	51,391	Jun 07 05:00 PM
Daly Richard J	President and CEO	Jun 04 '24	Option Exercise	4.01	40,000	160,400	252,147	Jun 05 05:00 PM
Daly Richard J	President and CEO	Jun 04 '24	Sale	15.97	17,323	276,735	234,824	Jun 05 05:00 PM
Harper Molly	Director	Jun 03 '24	Sale	16.30	5,333	86,949	0	Jun 05 05:00 PM
Tierney David S	Director	Apr 08 '24	Option Exercise	4.01	25,000	100,250	373,874	Apr 10 05:15 PM
Tierney David S	Director	Apr 08 '24	Sale	15.68	25,000	392,000	348,874	Apr 10 05:15 PM
Elsbernd Brian	Chief Compliance/Legal Officer	Mar 27 '24	Sale	16.44	25,000	411,000	124,433	Mar 28 04:45 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CPRX

Catalyst Pharmaceuticals Inc

Upgrade your FINVIZ experience